At BioScience, research and innovation are at the heart of everything we do. At IMCAS 2026, we’re putting our latest research into the spotlight – an in vitro study highlighting the biostimulatory effects of hybrid fillers, and in particular, Genefill DX. 

The study provides meaningful insights into how hybrid fillers that combine hyaluronic acid (HA) and dextranomer (DX) can influence biological activity linked to facial and skin rejuvenation.

This sets the stage for a deeper discussion we’ll be leading at our Smart Aesthetics symposium at IMCAS this January.

A Closer Look at the Study

In this lab-based in vitro study, researchers evaluated the behavior of Genefill DX in a controlled cellular environment, focusing on its rheological properties and biological effects.

Genefill DX demonstrated strong potential to stimulate the production of collagen (specifically types I, III, IV, and VI) and elastin, two key factors in maintaining healthy skin structure. It also demonstrated a balanced cytokine response, suggesting a favorable biological environment post-treatment. Notably, the study reported faster wound healing and long-lasting hydration, both of which contribute to skin resilience and comfort.

Compared to other filler types tested, including HA-only, HA+CaHA, CaHA, and PLLA, Genefill DX consistently outperformed in several categories, offering insight into how hybrid fillers may do more than restore volume. They may support skin texture, firmness, and long-term treatment durability. These are qualities that are becoming increasingly important in patient-centered aesthetic care.

While in vitro studies are not clinical trials, this data adds valuable scientific context to the way biostimulatory fillers are being evaluated and used in facial aesthetics.

‍

Bringing the Science to IMCAS 2026

At the IMCAS World Congress being held at Paris in January 2026, we’ll be exploring the clinical relevance of this study and several other key developments in biostimulatory and aesthetic filler strategies..

During our 90-minute symposium, Smart Aesthetics: Hybrid Biostimulatory Excellence for the Face, Targeted Precision for the Body, Dr. Gabriela Casabona will be leading a session titled The Future of Biostimulation in Facial Aesthetics. She’ll share her perspective on where the field is heading and how research like this is shaping modern treatment planning, moving beyond correction and toward techniques that support overall skin quality and treatment longevity.

Her talk is one part of a wider program that will also cover precision body contouring, hybrid filler performance, and real-world clinical insights from leading practitioners.

This is a session you don’t want to miss, so be sure to add the event to your calendar. 

‍

See You in Paris

If you’re attending IMCAS 2026, we invite you to be part of the conversation. From our symposium to expert sessions, we would love to engage in some meaningful conversations about shaping the future of aesthetics.

You can find us at our booth N214, from January 29th-31st at the Palais des Congrès de Paris.

If you’re looking to join our expert-led symposium, you can find us in Room 252, Level 2, on January 30th, 2026, at 14:00 (Paris, France, GMT+1)

We look forward to welcoming you to IMCAS 2026.

‍Reference for the study -
Ortiz-Flores RM, Escamilla-Sanchez A, Cidoncha-Morcillo B, Mastronardi L, Fontenete S, Garcia-Delgado R. Enhanced Facial Rejuvenation: Biostimulatory Effects of Hylan Gel Dermal Filler DX on Collagen Synthesis and Tissue Regeneration. Aesthetic Plast Surg. 2025 Oct 13.